Product
ISA101b
Aliases
Cemiplimab
3 clinical trials
3 indications
Indication
Human Papillomavirus Type 16 PositiveIndication
Cervical CancerClinical trial
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase II Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Positive Oropharyngeal Cancer Who Have Experienced Disease Progression With Prior Anti-PD-1 TherapyStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Cervical Cancer Who Have Experienced Disease Progression After First Line ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2023-05-22